Researchers evaluated the efficacy and safety of the Preserflo MicroShunt in treating primary open-angle glaucoma. The results showed significant reduction in intraocular pressure and medication burden without severe complications in both high-pressure and normal-pressure glaucoma. While the benefit-to-risk ratio was positive, some limitations were noted, including the short follow-up period and lack of medication washout period.

Source: Journal of Glaucoma